SM 20302

Drug Profile

SM 20302

Alternative Names: SM-20302

Latest Information Update: 30 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sumitomo Pharmaceuticals
  • Developer Nonindustrial source; Sumitomo Pharmaceuticals
  • Class Antiplatelets; Vascular disorder therapies
  • Mechanism of Action GPIIb-IIIa antagonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Coronary thrombosis; Thrombosis

Most Recent Events

  • 27 Sep 1999 Preclinical development for Coronary thrombosis in Japan (Unknown route)
  • 27 Sep 1999 Two preclinical studies have been added to the Thromboses and Ischaemic Heart Disease pharmacodynamics sections ,
  • 27 Sep 1999 Two preclinical studies have been added to the Thromboses pharmacodynamics section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top